Viz.ai announced that it received FDA 510(k) clearance for its Viz ICH Plus algorithm for providing volume measurements of brain bleeds.
Viz ICH Plus automates the process of identifying, labeling and quantifying the volume of segmentable brain structures on non-contrast computed tomography (NCCT) images. The company designed it to analyze intracranial hyperdensities, lateral ventricles and midline shifts. These metrics help to enable timely and informed brain bleed treatment decisions.
San Francisco-based Viz.ai developed the algorithm for quantifying intracerebral hemorrhage. This type of hemorrhage accounts for up to 15% of all strokes, the company says, with high morbidity and mortality rates. It requires a swift response with accurate brain bleed measurements to assess the severity of cases and monitor progression.
Radiologists, neurologists and neurosurgeons can incorporate Viz ICH Plus into their workflows. They can use it to automate the manual process of measuring brain bleeds. Viz.ai offers its ICH Plus software on its Viz.ai One enterprise platform solution.
Dr. Peter Kan said the ability and mobility with the algorithm “significantly enhances” the decision-making process. Kan, chair of the Dept. of Neurosurgery at the University of Texas Medical Branch, said it “marries precision with AI.” He added that it could transform the approach to intracerebral hemorrhage cases.
“At Viz.ai, our mission is rooted in advancing healthcare through innovation. Viz ICH Plus exemplifies our dedication to enhancing patient care by leveraging technology,” said Jayme Strauss, chief clinical officer at Viz.ai. “We are excited to introduce a product that bridges the gap between AI capabilities and improved patient outcomes.”